{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:08:00Z","timestamp":1790356080539,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10147-026-03157-1","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:32:44Z","timestamp":1785861164000},"page":"2481-2491","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictive value of TTF-1 expression for stratifying outcomes between dual ICI and chemoimmunotherapy in patients with PD-L1-negative NSCLC"],"prefix":"10.1007","volume":"31","author":[{"given":"Naoya","family":"Nishioka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nomizo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Imabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Iwanaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Chibana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayo","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuuya","family":"Nishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asuka","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Hamai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takenori","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taishi","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Tanimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Yoshimine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichiro","family":"Takaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Hibino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Oba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Sumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyasu","family":"Kaneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6945-281X","authenticated-orcid":false,"given":"Tadaaki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"3157_CR1","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/bs.vh.2017.05.007","volume":"106","author":"CA Phelps","year":"2018","unstructured":"Phelps CA, Lai SC, Mu D (2018) Roles of thyroid transcription factor 1 in lung cancer biology. Vitam Horm 106:517\u2013544","journal-title":"Vitam Horm"},{"key":"3157_CR2","doi-asserted-by":"publisher","first-page":"e607","DOI":"10.1016\/j.cllc.2020.05.014","volume":"21","author":"N Frost","year":"2020","unstructured":"Frost N, Zhamurashvili T, von Laffert M et al (2020) Pemetrexed-based chemotherapy is inferior to pemetrexed-free regimens in thyroid transcription factor 1 (TTF-1)-negative, EGFR\/ALK-negative lung adenocarcinoma: a propensity score matched pairs analysis. Clin Lung Cancer 21:e607\u2013e621","journal-title":"Clin Lung Cancer"},{"key":"3157_CR3","first-page":"9","volume":"13","author":"A Takeuchi","year":"2020","unstructured":"Takeuchi A, Oguri T, Yamashita Y et al (2020) Value of TTF-1 expression in non-squamous non-small-cell lung cancer for assessing docetaxel monotherapy after chemotherapy failure. Mol Clin Oncol 13:9","journal-title":"Mol Clin Oncol"},{"key":"3157_CR4","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378:2078\u20132092","journal-title":"N Engl J Med"},{"key":"3157_CR5","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","volume":"20","author":"H West","year":"2019","unstructured":"West H, McCleod M, Hussein M et al (2019) Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20:924\u2013937","journal-title":"Lancet Oncol"},{"key":"3157_CR6","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1200\/JCO.19.03136","volume":"38","author":"S Gadgeel","year":"2020","unstructured":"Gadgeel S, Rodr\u00edguez-Abreu D, Speranza G et al (2020) Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol 38:1505\u20131517","journal-title":"J Clin Oncol"},{"key":"3157_CR7","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1200\/JCO.22.01503","volume":"41","author":"JR Brahmer","year":"2023","unstructured":"Brahmer JR, Lee JS, Ciuleanu TE et al (2023) Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in CheckMate 227. J Clin Oncol 41:1200\u20131212","journal-title":"J Clin Oncol"},{"key":"3157_CR8","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","volume":"22","author":"L Paz-Ares","year":"2021","unstructured":"Paz-Ares L, Ciuleanu TE, Cobo M et al (2021) First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol 22:198\u2013211","journal-title":"Lancet Oncol"},{"key":"3157_CR9","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/S2213-2600(24)00185-1","volume":"12","author":"Y Shiraishi","year":"2024","unstructured":"Shiraishi Y, Nomura S, Sugawara S et al (2024) Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab-ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial. Lancet Respir Med 12:877\u2013887","journal-title":"Lancet Respir Med"},{"key":"3157_CR10","doi-asserted-by":"publisher","first-page":"412","DOI":"10.4143\/crt.2024.748","volume":"57","author":"N Nishioka","year":"2025","unstructured":"Nishioka N, Hata T, Yamada T et al (2025) Impact of TTF-1 expression on the prognostic prediction of patients with non-small cell lung cancer with PD-L1 expression levels of 1% to 49%, treated with chemotherapy vs. chemoimmunotherapy: a multicenter. Retrospective Study Cancer Res Treat 57:412\u2013421","journal-title":"Retrospective Study Cancer Res Treat"},{"key":"3157_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1399889","volume":"15","author":"N Nishioka","year":"2024","unstructured":"Nishioka N, Kawachi H, Yamada T et al (2024) Unraveling the influence of TTF-1 expression on immunotherapy outcomes in PD-L1-high non-squamous NSCLC: a retrospective multicenter study. Front Immunol 15:1399889","journal-title":"Front Immunol"},{"key":"3157_CR12","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48:452\u2013458","journal-title":"Bone Marrow Transplant"},{"key":"3157_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.lungcan.2017.03.015","volume":"108","author":"JB Schilsky","year":"2017","unstructured":"Schilsky JB, Ni A, Ahn L et al (2017) Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas. Lung Cancer 108:205\u2013211","journal-title":"Lung Cancer"},{"key":"3157_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010137","author":"A Nakao","year":"2022","unstructured":"Nakao A, Inoue H, Ikeuchi N et al (2022) Impact of results of TTF-1 immunostaining on efficacy of platinum-doublet chemotherapy in Japanese patients with nonsquamous non-small-cell lung cancer. J Clin Med. https:\/\/doi.org\/10.3390\/jcm12010137","journal-title":"J Clin Med"},{"key":"3157_CR15","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1111\/1759-7714.14560","volume":"13","author":"K Nakahama","year":"2022","unstructured":"Nakahama K, Kaneda H, Osawa M et al (2022) Association of thyroid transcription factor-1 with the efficacy of immune-checkpoint inhibitors in patients with advanced lung adenocarcinoma. Thorac Cancer 13:2309\u20132317","journal-title":"Thorac Cancer"},{"key":"3157_CR16","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.21037\/tlcr-23-331","volume":"12","author":"H Iso","year":"2023","unstructured":"Iso H, Hisakane K, Mikami E et al (2023) Thyroid transcription factor-1 (TTF-1) expression and the efficacy of combination therapy with immune checkpoint inhibitors and cytotoxic chemotherapy in non-squamous non-small cell lung cancer. Transl Lung Cancer Res 12:1850\u20131861","journal-title":"Transl Lung Cancer Res"},{"key":"3157_CR17","volume":"4","author":"Y Katayama","year":"2023","unstructured":"Katayama Y, Yamada T, Morimoto K et al (2023) TTF-1 expression and clinical outcomes of combined chemoimmunotherapy in patients with advanced lung adenocarcinoma: a prospective observational study. JTO Clin Res Rep 4:100494","journal-title":"JTO Clin Res Rep"},{"key":"3157_CR18","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.2147\/CMAR.S520436","volume":"17","author":"J Yamada","year":"2025","unstructured":"Yamada J, Jimbo N, Yamasaki N et al (2025) Diffuse and strong TTF-1 expression predicts response to pemetrexed-based immunochemotherapy in advanced lung adenocarcinoma. Cancer Manag Res 17:1599\u20131611","journal-title":"Cancer Manag Res"},{"key":"3157_CR19","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.21037\/tlcr-22-393","volume":"11","author":"R Ibusuki","year":"2022","unstructured":"Ibusuki R, Yoneshima Y, Hashisako M et al (2022) Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1\/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer. Transl Lung Cancer Res 11:2208\u20132215","journal-title":"Transl Lung Cancer Res"},{"key":"3157_CR20","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1007\/s00432-024-05916-x","volume":"150","author":"M Uhlenbruch","year":"2024","unstructured":"Uhlenbruch M, Kr\u00fcger S (2024) Effect of TTF-1 expression on progression free survival of immunotherapy and chemo-\/immunotherapy in patients with non-small cell lung cancer. J Cancer Res Clin Oncol 150:394","journal-title":"J Cancer Res Clin Oncol"},{"key":"3157_CR21","doi-asserted-by":"publisher","first-page":"462","DOI":"10.15252\/emmm.201606711","volume":"9","author":"M Guo","year":"2017","unstructured":"Guo M, Tomoshige K, Meister M et al (2017) Gene signature driving invasive mucinous adenocarcinoma of the lung. EMBO Mol Med 9:462\u2013481","journal-title":"EMBO Mol Med"},{"key":"3157_CR22","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.3892\/or.2012.2009","volume":"28","author":"YF Zu","year":"2012","unstructured":"Zu YF, Wang XC, Chen Y et al (2012) Thyroid transcription factor 1 represses the expression of Ki-67 and induces apoptosis in non-small cell lung cancer. Oncol Rep 28:1544\u20131550","journal-title":"Oncol Rep"},{"key":"3157_CR23","doi-asserted-by":"publisher","first-page":"494","DOI":"10.3346\/jkms.2003.18.4.494","volume":"18","author":"NH Myong","year":"2003","unstructured":"Myong NH (2003) Thyroid transcription factor-1 (TTF-1) expression in human lung carcinomas: its prognostic implication and relationship with wxpressions of p53 and Ki-67 proteins. J Korean Med Sci 18:494\u2013500","journal-title":"J Korean Med Sci"},{"key":"3157_CR24","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11845-018-1839-5","volume":"188","author":"MK Doherty","year":"2019","unstructured":"Doherty MK, O\u2019Connor E, Hannon D et al (2019) Absence of thyroid transcription factor-1 expression is associated with poor survival in patients with advanced pulmonary adenocarcinoma treated with pemetrexed-based chemotherapy. Ir J Med Sci 188:69\u201374","journal-title":"Ir J Med Sci"},{"key":"3157_CR25","doi-asserted-by":"publisher","DOI":"10.1177\/1010428317691186","volume":"39","author":"O Fiala","year":"2017","unstructured":"Fiala O, Pesek M, Skrickova J et al (2017) Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. Tumour Biol 39:1010428317691186","journal-title":"Tumour Biol"},{"key":"3157_CR26","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1097\/JTO.0b013e3182208ea8","volume":"6","author":"JM Sun","year":"2011","unstructured":"Sun JM, Han J, Ahn JS et al (2011) Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. J Thorac Oncol 6:1392\u20131399","journal-title":"J Thorac Oncol"},{"key":"3157_CR27","volume":"4","author":"Y Terashima","year":"2023","unstructured":"Terashima Y, Matsumoto M, Iida H et al (2023) Predictive impact of diffuse positivity for TTF-1 expression in patients treated with platinum-doublet chemotherapy plus immune checkpoint inhibitors for advanced nonsquamous NSCLC. JTO Clin Res Rep 4:100578","journal-title":"JTO Clin Res Rep"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03157-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03157-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03157-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:50:02Z","timestamp":1790355002000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03157-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3157"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03157-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9478780\/v1","asserted-by":"object"}]},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"21 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Tadaaki Yamada received research grants from Ono Pharmaceutical and Takeda Pharmaceutical, and has received speaking honoraria from Eli Lilly and Chugai-Roshe outside the purview of the submitted work. Koichi Azuma received personal fees from AstraZeneca, MSD, Bristol Myers Squibb, Ono Pharmaceutical, Takeda Pharmaceutical, Pfizer, and Chugai Pharmaceutical outside the purview of the submitted work. Asuka Okada received speaking honoraria from AstraZeneca, Nippon Kayaku, Bristol-Myers Squibb, Boehringer Ingelheim, Chugai-Roshe, Taiho Pharmaceutical, Kyowa Kirin, MSD, and Eli Lilly Japan outside the purview of the submitted work. Makoto Hibino received personal fees from Asahi Kasei Pharma Corporation, AstraZeneca, Boehringer Ingelheim, Bristol Myers, Chugai Pharmaceutical, and Eli Lilly outside the purview of the submitted work. Yosuke Tamura received speaking honoraria from AstraZeneca, Chugai- Pharmaceutical, MSD, Nippon Boehringer Ingelheim, and Ono Pharmaceutical outside the purview of the submitted work. Yasuhiro Goto received personal fees from AstraZeneca, Boehringer Ingelheim, Bristol Myers, Chugai Pharmaceutical, Kyowa Kirin International, Novartis, Ono Pharmaceutical, Pfizer, Takeda, and Taiho Pharmaceutical outside the purview of the submitted work. Toshiyuki Sumi received personal fees from AstraZeneca, Chugai Pharmaceutical, and Ono Pharmaceutical outside the purview of the submitted work. Hiroyasu Kaneda received speaking honoraria from AstraZeneca, Bristol-Myers Squibb, Chugai-Pharmaceutical, MSD, and Ono Pharmaceutical outside the purview of the submitted work. The remaining authors have no conflicts of interest to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study complied with the Declaration of Helsinki and was approved by the ethics review Board of Kurume University (Approval IRB No. 24116), which served as the central ethics committee for all participating centers.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent for the use of personal medical data was obtained using the opt-out method as described in the disclosure document.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ChatGPT (GPT-5.2, 2025 version, developed by OpenAI) was used to assist with English editing and language refinement during the abstract writing process. The authors reviewed and modified all content to ensure accuracy and originality. No AI-generated content was used as a primary source, and the authors confirm that there is no plagiarism in the AI-assisted material.","order":5,"name":"Ethics","label":"Declaration of AI and AI-assisted technologies in the writing process","group":{"name":"EthicsHeading","label":"Declarations"}}]}}